- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01698229
Collection of Cerebrospinal Fluid in Healthy Children
May 3, 2016 updated by: Weill Medical College of Cornell University
The purpose of this study is to obtain cerebrospinal fluid from healthy children already undergoing a lumbar puncture procedure at New York Presbyterian Hospital, to act as healthy controls when compared to children with late infantile neuronal ceroid lipofuscinosis (LINCL), a fatal neurodegenerative disease.
Study Overview
Status
Terminated
Intervention / Treatment
Detailed Description
obtain cerebrospinal fluid from healthy children already undergoing a lumbar puncture procedure at New York Presbyterian Hospital, to act as healthy controls when compared to children with late infantile neuronal ceroid lipofuscinosis (LINCL), a fatal neurodegenerative disease.
Study Type
Observational
Enrollment (Actual)
32
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Weill Cornell Medical College / New York Presbyterian Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 8 years (Child)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Subjects will be healthy controls (children ages 2 years to 8 years) undergoing a lumbar puncture at New York Presbyterian Hospital, for clinical care purposes.
They will be inpatients and outpatients.
Description
Inclusion Criteria:
- Males and females, ages 2 yrs to 8 yrs
- Children already undergoing a lumbar puncture procedure for clinical or diagnostic purposes
Exclusion Criteria:
- Presence of any significant neurological diseases, as judged by the co-investigators
- Presence of any significant medical conditions including cancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group 1
Study cohort is comprised of healthy children, ages 2yrs - 8yrs, who are already undergoing a lumbar puncture procedure at New York Presbyterian Hospital for clinical or diagnostic purposes.
|
Collecting a small amount of cerebrospinal fluid (5 mL) from healthy children, ages 2 yrs - 8 yrs, who are already undergoing a lumbar puncture procedure at New York Presbyterian Hospital for clinical or diagnostic purposes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cerebrospinal fluid (CSF)
Time Frame: 1 time point (once)
|
The primary study endpoint is the metabolic profiling of 32 samples of cerebrospinal fluid from healthy subjects, in comparison to 32 samples of CSF from children with LINCL, to determine whether there are biomarkers found in the cerebrospinal fluid that are associated with LINCL.
|
1 time point (once)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2011
Primary Completion (Actual)
December 1, 2015
Study Completion (Actual)
December 1, 2015
Study Registration Dates
First Submitted
August 15, 2012
First Submitted That Met QC Criteria
September 27, 2012
First Posted (Estimate)
October 2, 2012
Study Record Updates
Last Update Posted (Estimate)
May 4, 2016
Last Update Submitted That Met QC Criteria
May 3, 2016
Last Verified
May 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1111012024
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Batten Disease
-
Beyond Batten Disease FoundationTheranexusActive, not recruitingBatten DiseaseUnited States
-
Amicus TherapeuticsActive, not recruiting
-
Amicus TherapeuticsActive, not recruitingBatten Disease | CLN6United States
-
Emily de los ReyesRecruitingBatten Disease | CLN6United States
-
Jessica ScherrBioMarin PharmaceuticalEnrolling by invitationBatten Disease | Neuronal Ceroid-Lipofuscinoses | CLN2United States
-
Weill Medical College of Cornell UniversityNathan's Battle FoundationCompletedBatten Disease | Late-Infantile Neuronal Ceroid Lipfuscinosis
-
Universitätsklinikum Hamburg-EppendorfRecruitingBatten Disease | Neuronal Ceroid Lipofuscinosis | CLN1 Disease | CLN2 Disease | CLN3 Disease | CLN4 Disease | CLN5 Disease | CLN6 Disease | CLN7 Disease | CLN8 Disease | CLN10 Disease | CLN11 Disease | CLN12 Disease | CLN13 Disease | CLN14 DiseaseGermany
-
BioMarin PharmaceuticalCompletedBatten Disease | CLN2 Disease | Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 | Jansky-Bielschowsky DiseaseUnited States, Italy, Germany, United Kingdom
-
National Human Genome Research Institute (NHGRI)RecruitingDiabetes | Undiagnosed Diseases | Inherited Metabolic Disorders | Batten's Disease | Tay SachsUnited States
-
BioMarin PharmaceuticalCompletedBatten Disease | CLN2 Disease | Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 | Jansky-Bielschowsky Disease | CLN2 DisorderUnited States, Germany, Italy, United Kingdom
Clinical Trials on Group 1
-
Arkansas Children's Hospital Research InstituteRecruiting
-
Oslo University HospitalNorwegian Fund for Postgraduate Training in PhysiotherapyCompletedHealth-Related Quality of LifeNorway
-
Ichnos Sciences SAGlenmark Pharmaceuticals S.A.CompletedModerate to Severe Atopic DermatitisUnited States, Canada, Czechia, Germany, Poland
-
Weill Medical College of Cornell UniversityTerminatedChronic Obstructive Pulmonary Disease | COPDUnited States
-
Marmara UniversityCompletedStair up and Down, Amputation | Amputation,Stair up and DownTurkey
-
Shanghai General Hospital, Shanghai Jiao Tong University...UnknownRetinal Detachment | High Myopia | Macular HolesChina
-
Biruni UniversityCompleted
-
Biotronik SE & Co. KGBiotronik Japan, Inc.RecruitingImplantable Cardioverter Defibrillator(ICD)Japan
-
Riphah International UniversityCompleted
-
Hospital Universitario Central de AsturiasRecruiting